Clinical Trial · NCT07275463

[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression

Overview

The study should evaluate the \[99mTc\]Tc-DB8 accumulation in primary tumour of breast cancer patients with positive and negative estrogen receptor expression.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

Phase 2

Contacts

Vladimir I Chernov, MD, Prof (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07275463

Drug / Compound

DB8

Isotope(s):

Target(s):

GRPR

Ligand Class: Peptides

Eligibility

Inclusion

White blood cell count: \> 2.0 x 109/L
1. Subject is \> 18 years of age
Hemoglobin: \> 80 g/L
Hematological, liver and renal function test results within the following limits:
Availability of results from estrogen receptor status by Immunohistochemistry previously determined on material from the primary tumor

Exclusion

Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. Known HIV positive or chronically active hepatitis B or C
Second, non-breast malignancy
1. Any system therapy (chemo-/targeted therapy)
Administration of other investigational medicinal product within 30 days of screening
Active current autoimmune disease or history of autoimmune disease